Use of Enoxaparin in Patients with Chronic Kidney Disease: Safety Considerations

Author： Brophy Donald F.   Sica Domenic A.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.30, Iss.11, 2007-01, pp. : 991-994

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Desmopressin: Safety Considerations in Patients with Chronic Renal Disease

By Sica Domenic A.   Gehr Todd W.B.  

Drug Safety, Vol. 29, Iss. 7, 2006-01 ,pp. : 553-556

Adis International

Access to resources Recommend Favorite

Safety and tolerability of paricalcitol in patients with chronic kidney disease

By Dyer Christopher A  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 717-728

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

By Scheen André J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 5, 2013-05 ,pp. : 529-550

Informa Healthcare

Access to resources Recommend Favorite

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease

By Brophy Donald F   Ripley Elizabeth BD   Holdford David A  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1461-1469

Informa Healthcare

Access to resources Recommend Favorite

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite